CAAS Capital Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-3,900
Closed -$112K 622
2023
Q4
$112K Buy
+3,900
New +$118K 0.01% 407
2022
Q3
Sell
-18,900
Closed -$991K 966
2022
Q2
$991K Buy
+18,900
New +$963K 0.05% 374
2021
Q3
Sell
-18,500
Closed -$724K 1075
2021
Q2
$724K Buy
+18,500
New +$719K 0.01% 662
2020
Q3
Sell
-2,319
Closed -$81.3K 576
2020
Q2
$72K Buy
+2,319
New +$78.8K ﹤0.01% 387

Other funds holding PFE

CAAS Capital Management's PFE Position: Q1 2024 in Review

CAAS Capital Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 3,900 shares — an estimated $112K sold.

CAAS Capital Management first reported a position in PFE in Q2 2020 and held it in 4 quarters. The position peaked at $991K in Q2 2022. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • CAAS Capital Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • CAAS Capital Management sold 3,900 Pfizer shares in Q1 2024, an estimated $112K.
  • CAAS Capital Management first reported a position in Pfizer in Q2 2020 and held it in 4 quarters.
  • CAAS Capital Management's Pfizer position peaked at $991K in Q2 2022.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on CAAS Capital Management's 13F filing for Q1 2024, filed 26 Apr 2024.